peptide half-life raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-07-25 and is reviewed periodically as new material appears.
åºåˆ—层é¢çš„改动åŒæ—¶è§£å†³äº†ä¸¤ä¸ªé—®é¢˜ï¼Œå³é…¶è§£ç¨³å®šæ€§ä¸Žè‚¾è„清除速度。天然 GLP-1 在循环ä¸çš„åŠè¡°æœŸä»…约两分钟，主è¦è¢«äºŒè‚½åŸºè‚½é…¶-4 迅速ç活。酰化侧链与白蛋白的å¯é€†ç»“åˆå½¢æˆå¾ªçŽ¯å‚¨åº“，使分å缓慢释放并æŒç»æ¿€æ´»å—体。这ç§è®¾è®¡æ€è·¯åŽæ¥è¢«å¹¿æ³›ç”¨äºŽåŒç±»é•¿æ•ˆè‚½çš„å¼€å‘，属于该类è¯ç‰©åŒ–å¦æ”¹é€ 的典型范å¼ã€‚
Semaglutide 是一ç§ç»ç»“æž„ä¿®é¥°çš„èƒ°é«˜è¡€ç³–ç´ æ ·è‚½-1 类似物，其主链与内æºæ€§ GLP-1(7-36) 约有百分之ä¹å四的åºåˆ—一致性。第 8 ä½ä¸™æ°¨é…¸è¢« α-氨基异ä¸é…¸å–代，使二肽基肽酶-4 æ— æ³•è¯†åˆ«åŽŸæœ‰åˆ‡å‰²ä½ç‚¹ã€‚第 34 ä½èµ–氨酸æ¢ä¸ºç²¾æ°¨é…¸ï¼Œè¿›ä¸€æ¥é™ä½Žé…¶è§£é€ŸçŽ‡ã€‚第 26 ä½èµ–氨酸ç»é—´éš”基连接一æ¡å«å八个碳的二酸脂肪链，该侧链赋予分å与血浆白蛋白结åˆçš„能力。
该分å作为 GLP-1 å—体的选择性激动剂å‘挥作用，å—体属于 B ç±» G 蛋白å¶è”å—体家æ—，激活åŽç» Gs 通路æå‡ç»†èƒžå†…环腺苷酸水平。在胰腺 β 细胞，信å·ä¿ƒè¿›è‘¡è„ç³–ä¾èµ–æ€§çš„èƒ°å²›ç´ é‡Šæ”¾ï¼Œè¡€ç³–å低时该作用明显å‡å¼±ã€‚在胰岛 α ç»†èƒžï¼Œèƒ°é«˜è¡€ç³–ç´ åˆ†æ³Œå—到抑制。ä¸æž¢ç¥žç»ç³»ç»Ÿä¸Žèƒƒè‚ é“åŒæ ·å˜åœ¨å—体表达，相应信å·å‚与食欲调节以åŠèƒƒæŽ’空速率的é™ä½Žã€‚
Stability studies examine how temperature, pH, and moisture influence degradation rates over time. In aqueous solution, hydrolysis and deamidation accelerate as pH moves away from mildly acidic conditions. Light exposure and residual metal ions can also trigger oxidation of susceptible residues. Accelerated aging at elevated temperature is used to estimate shelf life, though extrapolation to room temperature carries uncertainty because individual degradation pathways do not always scale predictably.
Lyophilized semaglutide powder is typically held at minus twenty degrees Celsius for long-term storage. At that temperature, solid-state degradation reactions proceed slowly and the peptide remains intact for extended periods. Repeated freeze-thaw cycles are best avoided because they promote aggregation and can shift the proportion of monomeric peptide present. Working aliquots are often prepared so that each portion is thawed only once, and desiccant is placed inside the vial to limit moisture uptake.
Identity and purity are usually assessed by reverse-phase high-performance liquid chromatography coupled to mass spectrometry. Retention time and observed mass are compared against a reference standard run under identical conditions. Impurity profiles reveal deamidation products, oxidized methionine variants, and truncated fragments that arise during synthesis or storage. Peptide mapping through enzymatic digestion confirms the primary sequence, while amino acid analysis offers an independent check on overall composition.
| Property | Value | Notes |
|---|---|---|
| 分åå¼ | C187H291N45O59 | 按主链与 C18 二酸侧链计算 |
| 分åé‡ | 约 4113.6 é“尔顿 | 游离碱形å¼ï¼Œéšå离å略有差异 |
| 外观 | 白色至类白色冻干粉末 | å…·å¸æ¹¿æ€§ï¼Œéœ€å¹²ç‡¥ä¿å˜ |
| 溶解性 | 微溶于水，易溶于碱性缓冲液 | æº¶è§£æ€§éš pH å‡é«˜è€Œæ”¹å–„ |
| ç‰ç”µç‚¹ | 约 5.4 | å½±å“缓冲液选择与èšé›†å€¾å‘ |
The sequence incorporates alpha-aminoisobutyric acid at position 8, replacing the alanine found in the natural hormone. This substitution blocks the primary DPP-4 recognition site and contributes most of the enzymatic stability. Albumin binding further protects the peptide and reduces the frequency of administration required to maintain active plasma levels. Because the fatty acid chain increases lipophilicity, the compound is formulated as a solution rather than a simple aqueous buffer. Researchers describe the design as an incremental optimization of earlier GLP-1 analogs rather than a wholly new scaffold.
Reported molecular weight is approximately 4113.6 daltons for the free base, and the peptide is supplied as a lyophilized powder or in buffered liquid form depending on the intended use. It is freely soluble in water when formulated with appropriate excipients, though the unconjugated peptide shows limited stability at neutral pH over long periods. Analytical characterization typically relies on reversed-phase high-performance liquid chromatography and mass spectrometry. Purity specifications for research-grade material commonly exceed ninety-five percent by area. Isotopic and impurity profiles differ between suppliers.
Two principal therapeutic variants exist under separate regulatory filings, one indicated for glycemic control in type 2 diabetes and one for chronic weight management. Both use the same active molecule; differences lie in formulation strength, titration schedule, and labeling. Regulatory agencies in the United States and European Union approved injectable forms in 2017 and 2018 respectively. An oral tablet formulation received approval later, using a carrier molecule to enhance absorption across the gastric epithelium. Labeling differs by jurisdiction and by indication.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
The Shroud of Turin (Italian: Sindone di Torino), also known as the Holy Shroud (Italian: Sacra Sindone), is a length of linen cloth that bears a faint image of the front and back of a naked man. Because details of the image are consistent with traditional depictions of Jesus of Nazareth after his death by crucifixion, the shroud has been venerated by Christians for centuries, especially by members of the Catholic Church, as Jesus's shroud upon which his image was miraculously imprinted. The human image on the shroud can be discerned more clearly in a black-and-white photographic negative than in its natural sepia colour, an effect discovered in 1898 by Secondo Pia, who produced the first photographs of the shroud. This negative image is associated with a popular Catholic devotion to the Holy Face of Jesus. The documented history of the shroud dates back to 1354, when it began to be exhibited in the new collegiate church of Lirey, a village in north-central France. The shroud was denounced as a forgery by the bishop of Troyes, Pierre d'Arcis, in 1389. It was acquired by the House of Savoy in 1453 and later deposited in a chapel in Chambéry, where it was damaged by fire in 1532. In 1578, the Savoys moved the shroud to their new capital in Turin, where it has remained ever since. In 1694, it was moved to the altar in the Chapel of the Holy Shroud, which was designed for that purpose by the architect Guarino Guarini and which is connected to both the royal palace and the Turin Cathedral. It remained there until 1993, when it was moved to the cathedral.
Nuclear warfare and weapons are staple elements of speculative fiction. The War Game by Peter Watkins is a docudrama depicting a hypothetical nuclear attack on Britain. Fail Safe, directed by Sidney Lumet, is a 1964 Cold War techno-thriller presenting a dramatization of an unintended nuclear escalation triggered by a mechanical failure.
== External links == CRBN protein, human at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Overview of all the structural information available in the PDB for UniProt: Q96SW2 (Protein cereblon) at the PDBe-KB.
Numerous traditional methods exist for nitrile preparation by amine oxidation. Common methods include the use of potassium persulfate, Trichloroisocyanuric acid, or anodic electrosynthesis. In addition, several selective methods have been developed in the last decades for electrochemical processes. Several procedures employ nitroxyl radicals such as TEMPO or 4-acetamido-TEMPO as catalytic oxidants. These catalysts can be regenerated either by potassium peroxymonosulfate as the stoichiometric oxidant or electrochemically under applied potential. Another approach utilizes copper(I) chloride or copper(II) chloride as catalyst, molecular oxygen as the stoichiometric oxidant, and a molecular sieve to remove the water formed.
== Justification == Topical drug delivery is a route of administering drugs via the skin with the intent to provide therapeutic effects. This system usually provides a local effect on certain organs. In ancient times, people used herbs on wounds for relieving the inflammatory effect or as pain relievers. There are numerous dosage forms that can be used topically, including cream, ointment, lotion, patches, and other forms. The topical use has many advantages: avoiding first pass metabolism which can increase its bioavailability, being convenient and easy to apply to a large area, being easy to terminate the medication, and avoiding gastrointestinal irritations. All these can increase patient compliance. However, there are several disadvantages to this system – causing skin irritations and symptoms like rashes and itchiness may occur. Also, only small particles can pass through the skin, which limits the choice of drugs. Since skin is the main medium of the topical drug delivery system, its conditions determine the rate of skin penetration leading to affecting the pharmacokinetics of the drug. The temperature, pH value, and dryness of the skin need to be considered. There are some novel topical drugs in the market which can utilise the system as much as possible. This localized system provides topical therapeutic effects via skin, eyes, nose, and vagina to treat diseases. The most common usage is for local skin infections.
Sources: en.wikipedia.org
=== Precursor to other peroxide compounds === Hydrogen peroxide is a weak acid, forming hydroperoxide or peroxide salts with many metals. It also converts metal oxides into the corresponding peroxides. For example, upon treatment with hydrogen peroxide, chromic acid (CrO3 and H2SO4) forms a blue peroxide CrO(O2)2.
== Reception == WHO director-general Tedros Adhanom, who was not directly involved with the investigation, said he was ready to dispatch additional missions involving specialist experts and that further research was required. He said in a statement, "Some explanations may be more probable than others, but for now all possibilities remain on the table". He also said, "We have not yet found the source of the virus, and we must continue to follow the science and leave no stone unturned as we do." Tedros also called on China to provide "more timely and comprehensive data sharing" as part of future investigations. News outlets noted that though it was unrealistic to expect quick and huge results from the report, it "offered few clear-cut conclusions regarding the start of the pandemic", "failed to audit the Chinese official position at some parts of the report", and was "biased according to critics". Other scientists praised how the report details the pathways that can shed light on the origin, if explored later. After the publication of the report, politicians, talk show hosts, journalists, and some scientists advanced unsupported claims that SARS-CoV-2 may have come from the WIV. In the United States, calls to investigate a laboratory leak reached a "fever pitch", fueling aggressive rhetoric resulting in antipathy towards people of Asian ancestry, and the bullying of scientists. The United States, European Union, and 13 other countries criticised the WHO-convened study, calling for transparency from China and access to the raw data and original samples.
Raw regular tofu is 85% water, 8% protein, 2% carbohydrates, and 5% fat (table). In a reference amount of 100 g (3.5 oz), tofu supplies 76 calories, and is a rich source (20% or more of the Daily Value) of calcium, copper, iron, and manganese (table).
The reaction is reliable and proceeds to completion. Less unreacted starting material will simplify analysis. Also, this allows a small amount of analyte to be used. The reaction is general, allowing a wide range of substrates, yet specific to a single functional group, reducing complicating interference. The products are relatively stable, and form no degradation products within a reasonable period, facilitating analysis. Some examples of good derivatization reactions are the formation of esters and amides via acyl chlorides.
== Chemical-physical characteristics == It is a dense red-violet liquid, but the color can vary based on the pH of the environment (reddish in an acidic environment, bluish in a basic environment). Chemically, enocyanin is a mixture of mono and dimethyl compounds of multiple anthocyanidins, it is soluble in hydroalcoholic solutions and insoluble in lipid solvents. The substance is listed together with other anthocyanins among food additives with the acronym "E163" (grape skin extract) and is marketed in the form of a dark red-purple powder to be dissolved in water or directly liquid. It is extracted from by-products of red winemaking (e.g. grape marc) and must be stored in a protected environment, preferably in the dark and away from heat sources. It fears humidity, oxidation and photodegradation, which transform it into insoluble brownish compounds typically found in poorly stored red wines.
Sources: en.wikipedia.org
The island chain is a western continuation of the Aleutian Range on the mainland. The great majority of the islands bear evident marks of volcanic origin, and there are numerous volcanic cones on the north side of the chain, some of them active; many of the islands, however, are not wholly volcanic, but contain crystalline or sedimentary rocks, and also amber and beds of lignite. The coasts are rocky and surf-worn, and the approaches are exceedingly dangerous, the land rising immediately from the coasts to steep, bold mountains. These volcanic islands reach heights of 6,200 feet (1,900 m). Makushin Volcano (5,691 feet (1,735 m)) on Unalaska Island, is not quite visible from within the town of Unalaska, though the steam rising from its cone is visible on a (rare) clear day. Residents of Unalaska need only to climb one of the smaller hills in the area, such as Pyramid Peak or Mt. Newhall, to get a good look at the snow-covered cone. The volcanic Bogoslof and Fire Islands, which rose from the sea in 1796 and 1883 respectively, lie about 30 miles (50 km) west of Unalaska Bay. In 1906, a new volcanic cone rose between the islets of Bogoslof and Grewingk, near Unalaska, followed by another in 1907. These cones were nearly demolished by an explosive eruption on September 1, 1907. In 2017, the volcanic cone erupted sending ash and ice particles 30,000 feet (9000 m) into the air.
== Discovery == The N-acetylmuramoyl-L-alanine amidase enzymatic activity was first observed in human and mouse serum in 1981 by Branko Ladešić and coworkers. The enzyme (abbreviated NAMLAA) was then purified from human serum by this and other groups. The sequence of 15 N-terminal amino acids of NAMLAA was identified, but the cDNA for the protein was not cloned and the gene encoding NAMLAA was not known. In 2000, Dan Hultmark and coworkers discovered a family of 12 Peptidoglycan Recognition Protein (PGRP) genes in Drosophila melanogaster and by homology searches of available human and mouse sequences predicted the presence of long forms of human and mouse PGRPs, which they named PGRP-L by analogy to long forms of insect PGRPs. In 2001, Roman Dziarski and coworkers discovered and cloned three human PGRPs, named PGRP-L, PGRP-Iα, and PGRP-Iβ (for long and intermediate size transcripts), and established that human genome codes for a family of 4 PGRPs: PGRP-S (short PGRP) and PGRP-L, PGRP-Iα, and PGRP-Iβ. Subsequently, the Human Genome Organization Gene Nomenclature Committee changed the gene symbols of PGRP-S, PGRP-L, PGRP-Iα, and PGRP-Iβ to PGLYRP1 (peptidoglycan recognition protein 1), PGLYRP2 (peptidoglycan recognition protein 2), PGLYRP3 (peptidoglycan recognition protein 3), and PGLYRP4 (peptidoglycan recognition protein 4), respectively, and this nomenclature is currently also used for other mammalian PGRPs. Sergei Kiselev and coworkers also independently cloned mouse PGLYRP2 (which they named TagL).
=== Cancer === Since its initial discovery, Wnt signaling has had an association with cancer. When Wnt1 was discovered, it was first identified as a proto-oncogene in a mouse model for breast cancer. The fact that Wnt1 is a homolog of Wg shows that it is involved in embryonic development, which often calls for rapid cell division and migration. Misregulation of these processes can lead to tumor development via excess cell proliferation. Canonical Wnt pathway activity is involved in the development of benign and malignant breast tumors. The role of Wnt pathway in tumor chemoresistance has been also well documented, as well as its role in the maintenance of a distinct subpopulation of cancer-initiating cells. Its presence is revealed by elevated levels of β-catenin in the nucleus and/or cytoplasm, which can be detected with immunohistochemical staining and Western blotting. Increased β-catenin expression is correlated with poor prognosis in breast cancer patients. This accumulation may be due to factors such as mutations in β-catenin, deficiencies in the β-catenin destruction complex, most frequently by mutations in structurally disordered regions of APC, overexpression of Wnt ligands, loss of inhibitors and/or decreased activity of regulatory pathways (such as the Wnt/calcium pathway). Breast tumors can metastasize due to Wnt involvement in EMT. Research looking at metastasis of basal-like breast cancer to the lungs showed that repression of Wnt/β-catenin signaling can prevent EMT, which can inhibit metastasis.
=== Burden of illness === Sjögren's disease is associated with a high burden of illness, and has been shown to markedly reduce quality of life (QoL), with a significant impact on the ability to work resulting from increased rates of disability. The reduction in QoL is similar to that seen in other chronic conditions such as rheumatoid arthritis, lupus, and fibromyalgia.
=== Ankylosis === Ankylosis is a condition where the cementum of the tooth's root fuses with the bone that is around the tooth. The osseous tissue replaces the periodontal ligament which causes the tooth to be fixed and cannot undergo eruptive change. Ankylosis usually occurs in primary molars; however, it can also take place in other primary teeth, as well as secondary dentition. Ankylosis is common in the anterior tooth after trauma and can be referred to as replacement resorption. In this process PDL cells are destroyed and as a result the cells of the alveolar bone will perform most of the healing. Radiographic examination of a patient with ankylosis may also reveal a loss of the PDL and bony bridging.
Sources: en.wikipedia.org
差别集ä¸åœ¨ä¸‰å¤„：第 8 ä½æ®‹åŸºè¢«éžå¤©ç„¶æ°¨åŸºé…¸å–代，第 34 ä½æ¢æˆç²¾æ°¨é…¸ï¼Œç¬¬ 26 ä½å¢žåŠ 一æ¡è„‚肪酸侧链。å‰ä¸¤å¤„改动é™ä½Žé…¶è§£é€ŸçŽ‡ï¼Œä¾§é“¾åˆ™é€šè¿‡ç™½è›‹ç™½ç»“åˆå»¶é•¿å¾ªçŽ¯æ—¶é—´ã€‚综åˆç»“果是åŠè¡°æœŸä»Žçº¦ä¸¤åˆ†é’Ÿå»¶é•¿åˆ°çº¦ä¸€å‘¨ã€‚
èƒ°å²›ç´ é‡Šæ”¾éœ€è¦ç»†èƒžå†…环腺苷酸与钙信å·å‡é«˜ï¼ŒåŒæ—¶ä¾èµ–è‘¡è„糖代谢产生的ååŒä¿¡å·ã€‚血糖水平较低时ååŒä¿¡å·ä¸è¶³ï¼Œåˆ†æ³Œå¢žå¼ºæœ‰é™ã€‚这一机制在é™ç³–效果与低血糖风险之间æ供了缓冲。
白蛋白结åˆæ˜¯ä¸»è¦åŽŸå› ，它å‡å°‘肾å°çƒæ»¤è¿‡å¹¶ä¿æŠ¤åˆ†åå…å—蛋白酶é™è§£ã€‚åºåˆ—修饰带æ¥çš„酶解抵抗åŒæ ·ä¸å¯å¿½ç•¥ï¼ŒäºŒè€…å…±åŒä½œç”¨ã€‚脂肪链的ç–水性还会影å“组织分布，但其对总åŠè¡°æœŸçš„贡献程度ä»åœ¨ç ”究之ä¸ã€‚
Manufacturers commonly state multi-year stability when the powder is kept dry and frozen. Actual shelf life depends on residual moisture, vial sealing, and storage temperature. A re-test by chromatography is the only way to confirm remaining purity.